3.91
price down icon4.17%   -0.17
after-market After Hours: 3.96 0.05 +1.28%
loading
Precigen Inc stock is traded at $3.91, with a volume of 4.31M. It is down -4.17% in the last 24 hours and up +1.56% over the past month. Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
See More
Previous Close:
$4.08
Open:
$4.12
24h Volume:
4.31M
Relative Volume:
0.48
Market Cap:
$1.17B
Revenue:
$6.23M
Net Income/Loss:
$-95.90M
P/E Ratio:
-10.03
EPS:
-0.39
Net Cash Flow:
$-68.47M
1W Performance:
+10.76%
1M Performance:
+1.56%
6M Performance:
+155.56%
1Y Performance:
+317.20%
1-Day Range:
Value
$3.85
$4.18
1-Week Range:
Value
$3.39
$4.24
52-Week Range:
Value
$0.6513
$5.225

Precigen Inc Stock (PGEN) Company Profile

Name
Name
Precigen Inc
Name
Phone
301-556-9900
Name
Address
20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD
Name
Employee
25
Name
Twitter
@precigen
Name
Next Earnings Date
2025-03-19
Name
Latest SEC Filings
Name
PGEN's Discussions on Twitter

Compare PGEN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
PGEN
Precigen Inc
3.91 1.44B 6.23M -95.90M -68.47M -0.39
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
426.44 109.29B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
464.90 62.13B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
584.74 61.40B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
814.17 51.39B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
313.54 34.68B 4.56B -176.77M 225.30M -1.7177

Precigen Inc Stock (PGEN) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-15-25 Upgrade JP Morgan Underweight → Neutral
Mar-22-24 Downgrade JP Morgan Neutral → Underweight
May-23-23 Initiated JP Morgan Neutral
Nov-18-22 Initiated Cantor Fitzgerald Overweight
Feb-25-21 Initiated Stifel Buy
Feb-22-21 Initiated Wells Fargo Overweight
Feb-18-21 Initiated B. Riley Securities Buy
May-08-20 Initiated H.C. Wainwright Buy
View All

Precigen Inc Stock (PGEN) Latest News

pulisher
Oct 22, 2025

Tools to assess Precigen Inc.’s risk profileEarnings Miss & Long-Term Growth Stock Strategies - newser.com

Oct 22, 2025
pulisher
Oct 21, 2025

How to integrate Precigen Inc. into portfolio analysis toolsStop Loss & Real-Time Volume Surge Alerts - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

Real time social sentiment graph for Precigen Inc.July 2025 Analyst Calls & Safe Entry Point Alerts - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

Earnings visualization tools for Precigen Inc.2025 AllTime Highs & Risk Controlled Stock Alerts - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

How Precigen Inc. stock performs in high volatility marketsVolume Spike & Weekly High Momentum Picks - newser.com

Oct 21, 2025
pulisher
Oct 20, 2025

What technical models suggest about Precigen Inc.’s comebackOil Prices & Free Risk Controlled Daily Trade Plans - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

Analyzing net buyer seller activity in Precigen Inc.July 2025 Trade Ideas & Safe Entry Point Alerts - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

How to monitor Precigen Inc. with trend dashboardsEarnings Miss & High Return Trade Opportunity Guides - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

Is now a turning point for Precigen Inc.Trade Performance Summary & Weekly Top Stock Performers List - newser.com

Oct 20, 2025
pulisher
Oct 19, 2025

Why Precigen Inc. stock appeals to dividend seekersEarnings Growth Report & Trade Opportunity Analysis Reports - newser.com

Oct 19, 2025
pulisher
Oct 19, 2025

Can Precigen Inc. stock deliver strong Q4 earningsJuly 2025 Macro Moves & Trade Opportunity Analysis - nchmf.gov.vn

Oct 19, 2025
pulisher
Oct 18, 2025

Will Precigen Inc. stock deliver long term returnsPortfolio Value Summary & Growth-Oriented Investment Plans - nchmf.gov.vn

Oct 18, 2025
pulisher
Oct 18, 2025

Precigen Stock Surges Amid Promising Clinical Trial Outcomes - timothysykes.com

Oct 18, 2025
pulisher
Oct 18, 2025

Why Precigen Inc. stock is seen as undervaluedTrade Performance Summary & Risk Managed Investment Entry Signals - nchmf.gov.vn

Oct 18, 2025
pulisher
Oct 18, 2025

A Look at Precigen (PGEN) Valuation After PAPZIMEOS’ Full FDA Approval and Clinical Breakthroughs - Sahm

Oct 18, 2025
pulisher
Oct 17, 2025

What analyst consensus says on Precigen Inc. stockQuarterly Trade Report & Consistent Profit Trading Strategies - nchmf.gov.vn

Oct 17, 2025
pulisher
Oct 17, 2025

Pharma News: What dividend safety score for Precigen Inc. stock2025 Trade Ideas & Reliable Volume Spike Trade Alerts - nchmf.gov.vn

Oct 17, 2025
pulisher
Oct 17, 2025

Precigen, Inc. (PGEN) Stock Analysis: Unlocking a 136% Upside Potential in Biotech Innovation - DirectorsTalk Interviews

Oct 17, 2025
pulisher
Oct 17, 2025

A Look at Precigen (PGEN) Valuation Following FDA Approval of PAPZIMEOS for Recurrent Respiratory Papillomatosis - Yahoo Finance

Oct 17, 2025
pulisher
Oct 16, 2025

Precigen, Inc. Hits Day High with 10.31% Surge in Strong Intraday Performance - Markets Mojo

Oct 16, 2025
pulisher
Oct 16, 2025

Patient Capital's Q3 2025 Top Contributors And Detractors - Seeking Alpha

Oct 16, 2025
pulisher
Oct 16, 2025

Minimal Residual Disease Pipeline 2025: Pioneering Clinical Developments by 8+ Global Innovators – DelveInsight | Highlighting Genentech, AmMax Bio, Elicio Therapeutics, Precigen Inc - Barchart.com

Oct 16, 2025
pulisher
Oct 14, 2025

Will a bounce in Precigen Inc. offer an exitGap Up & Fast Entry Momentum Trade Alerts - newser.com

Oct 14, 2025
pulisher
Oct 13, 2025

Precigen Inc83% of Responders Show Continued Complete Response After 36 Months - 富途牛牛

Oct 13, 2025
pulisher
Oct 13, 2025

Precigen Inc (I5X.SG) stock price, news, quote and history - Yahoo

Oct 13, 2025
pulisher
Oct 13, 2025

3 High Growth Stocks With Strong Insider Ownership - simplywall.st

Oct 13, 2025
pulisher
Oct 13, 2025

Institutional scanner results for Precigen Inc.July 2025 Fed Impact & Scalable Portfolio Growth Methods - newser.com

Oct 13, 2025
pulisher
Oct 13, 2025

PGEN SEC FilingsPrecigen Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Oct 13, 2025
pulisher
Oct 13, 2025

Precigen Says Drug for Rare Respiratory Disease Shows Durable Outcomes - MarketScreener

Oct 13, 2025
pulisher
Oct 13, 2025

Precigen reports durable responses to RRP treatment in long-term data - Investing.com Canada

Oct 13, 2025
pulisher
Oct 13, 2025

Precigen reports durable responses to RRP treatment in long-term data By Investing.com - Investing.com South Africa

Oct 13, 2025
pulisher
Oct 13, 2025

Precigen (PGEN) Showcases Promising Results for PAPZIMEOS in Tre - GuruFocus

Oct 13, 2025
pulisher
Oct 13, 2025

83% of Complete Responders Ongoing at 36 Months — Precigen's PAPZIMEOS Shows Durable Responses - Stock Titan

Oct 13, 2025
pulisher
Oct 13, 2025

Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis - Yahoo Finance

Oct 13, 2025
pulisher
Oct 11, 2025

Precigen, Inc.Common Stock (NQ: PGEN - FinancialContent

Oct 11, 2025
pulisher
Oct 10, 2025

Using flow based indicators on Precigen Inc.Market Volume Summary & Free Technical Pattern Based Buy Signals - newser.com

Oct 10, 2025

Precigen Inc Stock (PGEN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$36.84
price down icon 1.71%
$88.06
price up icon 0.87%
$29.92
price down icon 0.70%
$106.23
price down icon 0.62%
$160.40
price down icon 2.97%
biotechnology ONC
$313.54
price down icon 0.70%
Cap:     |  Volume (24h):